Refine
Has Fulltext
- yes (32)
Is part of the Bibliography
- yes (32)
Document Type
- Journal article (25)
- Preprint (4)
- Conference Proceeding (3)
Language
- English (32)
Keywords
- PET (11)
- Positronen-Emissions-Tomografie (10)
- neuroendocrine tumor (8)
- theranostics (7)
- PSMA (5)
- prostate cancer (5)
- CXCR4 (4)
- PET/CT (4)
- PRRT (4)
- RADS (4)
- SPECT (4)
- SSTR (4)
- radioligand therapy (4)
- 18F-DCFPyL (3)
- DaTscan (3)
- Prostate Cancer (3)
- molecular imaging (3)
- peptide receptor radionuclide therapy (3)
- positron emission tomography (3)
- prostate-specific membrane antigen (3)
- somatostatin receptor (3)
- 18F-FDG (2)
- Ioflupane (2)
- PSMA-PET (2)
- PSMA-RADS (2)
- Parkinson (2)
- Parkinson Disease (2)
- Parkinson-Krankheit (2)
- Positron Emission Tomography (2)
- SSTR-RADS (2)
- TKI (2)
- Virchow Node (2)
- [177Lu]-DOTATATE/-DOTATOC (2)
- [68Ga] (2)
- chemokine receptor (2)
- personalized medicine (2)
- reporting and data system (2)
- tumor heterogeneity (2)
- vandetanib (2)
- 123I-Ioflupane (1)
- 177Lu (1)
- 18F-DCFPL (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATOC (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- C-X-C motif chemokine receptor 4 (1)
- COVID-19 (1)
- CTCAE (1)
- CXCR4-targeting (1)
- DOTATOC (1)
- GCA (1)
- Ganglia (1)
- HMDP hydroxymethylene diphosphonate (1)
- Imaging pitfalls (1)
- MAG3 (1)
- MI-RADS (1)
- MRI (1)
- Myocardial-perfusion SPECT (1)
- NEC (1)
- NET (1)
- PMR (1)
- PROMISE (1)
- PSMA I&T (1)
- PSMA-617 (1)
- Pancreas (1)
- Parkinsonism (1)
- Parkinson’s disease (1)
- Pitfall (1)
- Prostata (1)
- RLT (1)
- Radiofluorine (1)
- Radiotracer (1)
- SARS-CoV-2 (1)
- SPECT/CT (1)
- SSTR-PET (1)
- SUV (1)
- Single-Photon-Emissions-Computertomographie (1)
- Tracer (1)
- [177Lu]/[90Y]PentixaTher (1)
- [18F]FDG PET/CT (1)
- [68Ga]DOTATOC (1)
- [68Ga]PentixaFor (1)
- [68Ga]Pentixafor (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{177}\)Lu (1)
- \(^{18}\)F (1)
- \(^{68}\)Ga (1)
- ageing (1)
- combination (1)
- ejection fraction (1)
- endoradiotherapy (1)
- fibroblast activation protein (1)
- giant cell arteritis (1)
- hematotoxicity (1)
- inflammation (1)
- interobserver (1)
- interreader (1)
- left-ventricular function (1)
- matched pair (1)
- medullary thyroid carcinoma (1)
- mouse (1)
- nephrotoxicity (1)
- neuroendocrine neoplasia (1)
- ollimator (1)
- pancreas (1)
- papillary thyroid carcinoma (PTC) (1)
- polymyalgia rheumatica (1)
- post-reconstruction filtering (1)
- prostate-specific membrane antigen (PSMA) (1)
- quality (1)
- quantification (1)
- radioiodine (1)
- renal scintigraphy (1)
- reporting and data systems (1)
- scanner (1)
- selpercatinib (1)
- skeletal (1)
- small animal SPECT (1)
- small-animal imaging (1)
- solid tumors (1)
- somatostatin receptor (SSTR) (1)
- standardization (1)
- standardized reporting (1)
- thyroid carcinoma (TC) (1)
- tyrosine kinase inhibitor (1)
- vasculature (1)
- vasculitis (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (32)
- Medizinische Klinik und Poliklinik II (8)
- Medizinische Klinik und Poliklinik I (5)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (4)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (3)
- Pathologisches Institut (2)
- Urologische Klinik und Poliklinik (2)
- Comprehensive Cancer Center Mainfranken (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (16)
Background
Labelled with lutetium-177, the urea-based small molecules PSMA I&T and PSMA-617 are the two agents most frequently used for radioligand therapy (RLT) in patients with advanced metastatic castration-resistant and prostate-specific membrane antigen (PSMA) expressing prostate cancer (mCRPC). In this matched-pair analysis, we aimed to compare the toxicity and efficacy of both agents for PSMA-directed RLT.
Materials and methods
A total of 110 mCRPC patients from two centres were accrued, 55 individuals treated with [\(^{177}\)Lu]Lu-PSMA I&T, and a matched cohort of 55 patients treated with [\(^{177}\)Lu]Lu-PSMA-617. Matching criteria included age at the first cycle, Gleason score, prostate-specific antigen (PSA) values, and previous taxane-based chemotherapy. Using common terminology criteria for adverse events (CTCAE v. 5.0), toxicity profiles were investigated (including bone marrow and renal toxicity). Overall survival (OS) between both groups was compared.
Results
Toxicity assessment revealed grade III anaemia in a single patient (1.8%) for [\(^{177}\)Lu]Lu-PSMA I&T and five (9.1%) for [\(^{177}\)Lu]Lu-PSMA-617. In addition, one (1.9%) grade III thrombopenia for [\(^{177}\)Lu]Lu-PSMA-617 was recorded. Apart from that, no other grade III/IV toxicities were present. A median OS of 12 months for patients treated with [\(^{177}\)Lu]Lu-PSMA I&T did not differ significantly when compared to patients treated with [\(^{177}\)Lu]Lu-PSMA-617 (median OS, 13 months; P = 0.89).
Conclusion
In this matched-pair analysis of patients receiving one of the two agents most frequently applied for PSMA RLT, the rate of clinically relevant toxicities was low for both compounds. In addition, no relevant differences for OS were observed.